NEW YORK– Carlin Consumer Health (“Carlin”), a preeminent consumer health business that specializes in acquiring leading over-the-counter (“OTC”) brands, today announced that it has acquired PENETREX® (“Penetrex”) from Wellbeam Consumer Health (“Wellbeam”). The financial terms of the transaction were not disclosed.
Penetrex is a leading joint and muscle care brand trusted by millions of consumers. As part of the transaction, Penetrex will now become a brand within the Carlin Consumer Health portfolio.
“We are very excited to add Penetrex to our portfolio of leading OTC brands,” said Wael Fayad, Chairman of Carlin Consumer Health and a Partner at Hildred Capital. “We believe that Penetrex will be an important driver of Carlin’s growth in the years to come and is highly complementary to the world-class consumer health brands that are in our portfolio.”
“Penetrex is an ideal fit for Carlin’s portfolio and their team’s experience and expertise in the consumer health market will be instrumental in helping to further grow and expand the brand,” said Chris Marschall, CEO of Wellbeam Consumer Health. “We wish the Carlin team success as they work to seamlessly integrate Penetrex into their growing portfolio.”
Founded in 2022, Carlin Consumer Health is sponsored by Hildred Capital, Bourne Partners Strategic Capital, and The Emerson Group—and markets leading consumer health brands.
Sidley Austin LLP served as legal adviser to Carlin. Lincoln International acted as exclusive financial adviser and Jones Day as legal adviser to Wellbeam.
